A Trial of RSL Versus WL for Malignant Breast Disease
Status: | Recruiting |
---|---|
Healthy: | No |
Age Range: | 20 - 99 |
Updated: | 10/31/2018 |
Start Date: | July 2015 |
End Date: | July 2020 |
Contact: | Sapana Shah |
Email: | Sapana.Shah@atriumhealth.org |
A Randomized Single-Center Superiority Trial of Radioactive Seed Localization Versus Needle Localization for Malignant Breast Disease.
The purpose of this randomized trial is to determine the superiority of utilizing radioactive
seed localization (RSL) over wire-guided localization (WL) for palpable or non-palpable
malignant lesions in patients undergoing breast conservation surgery (BCS).
seed localization (RSL) over wire-guided localization (WL) for palpable or non-palpable
malignant lesions in patients undergoing breast conservation surgery (BCS).
Consented and eligible subjects will be randomized to either radioactive seed localization or
wire localization and stratified by surgeon and invasive versus DCIS prior to localization.
Subjects on both arms will undergo breast conservation surgery including surgical specimen
removal. Specimens will be grossed according to standard of care procedures. Localization,
breast conservation surgery, and post-operative appointments will follow standard of care
guidelines. Surveys will be administered according to the study calendar to the radiologist,
surgeon, pathologist, and subject for data collection.
wire localization and stratified by surgeon and invasive versus DCIS prior to localization.
Subjects on both arms will undergo breast conservation surgery including surgical specimen
removal. Specimens will be grossed according to standard of care procedures. Localization,
breast conservation surgery, and post-operative appointments will follow standard of care
guidelines. Surveys will be administered according to the study calendar to the radiologist,
surgeon, pathologist, and subject for data collection.
Inclusion Criteria:
- Female
- 20 to 99 years of age
- Breast lesion necessitating image-guided excision
- Unifocal disease
- Breast-conservation candidate
- Biopsy-proven malignant breast lesion including by not limited to invasive ductal
carcinoma, invasive lobular carcinoma, and ductal carcinoma in situ
- Signed written informed consent document by the subject and/or a LAR
Exclusion Criteria:
- Male
- Multifocal or multicentric disease
- Receiving neoadjuvant chemotherapy
- Pregnant or breastfeeding
- Locally advanced disease
- Breast conservation contraindication such as inability to receive whole breast
radiation therapy, inability to tolerate localization procedure, inability to lay flat
or prone for radiation, and undesirable tumor to breast ratio
- Prior breast cancer on ipsilateral side
- Unable or unwilling to adhere to post-localization instructions (e.g. timely seed
removal)
We found this trial at
1
site
Click here to add this to my saved trials